Answers are grounded in this paper and cite their sources.
Somatic mutations with low variant allele frequencies offer a highly sensitive lens for detecting cancer relapse driven by diverse causes, including clonal evolution and therapy resistance. Advances in next-generation sequencing have enabled robust subclonal variant identification that typically fall below conventional detection limits, supporting a comprehensive understanding of individual molecular profiles that can lead to relapse. These low-level alterations frequently emerge before clinical or radiological relapse and can inform response-adaptive treatment decisions. This review integrates the current biological and technical insights into low-frequency mutations and evaluates their emerging roles in tumor relapse management and precision oncology.
No takes yet. Share an insight, caveat, or question.
Gerald Prince (1990) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: